Carl Marks Securities Successfully Advises Kewaunee Scientific Corporation on $55 Million Acquisition of Nu Aire

Complementary Acquisition Expands Kewaunee’s Product Offerings and Market Reach

Carl Marks Securities, an affiliate of middle market investment bank Carl Marks Advisors, today announced that it has successfully advised Kewaunee Scientific Corporation (“Kewaunee”), a global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, on its acquisition of Nu Aire, a Minneapolis-based manufacturer of equipment for a diverse range of laboratory and pharmacy environments.

Founded in 1906 and headquartered in Statesville, North Carolina, Kewaunee designs and manufactures laboratory, healthcare, and technical furniture products for both domestic and international markets out of facilities in Statesville and Bangalore, India. Kewaunee’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

The acquisition of Nu Aire will provide Kewaunee with a more robust, diversified distribution network to meet global laboratory needs. Nu Aire is a recognized market leader whose product portfolio and well-developed channel strategy complements Kewaunee’s existing offerings.

“The acquisition marks a transformative moment for both companies,” said Chris Parisi, Partner at Carl Marks Advisors. “The combined organization, which is poised to capitalize on secular tailwinds and ongoing global investments in the life sciences, healthcare, and education sectors, will benefit from expanded product offerings and market reach.”

“We have maintained an advisory relationship with Kewaunee for many years and are proud to have played a role in the successful strategic acquisition of Nu Aire by Kewaunee,” added Evan Tomaskovic, Managing Partner at Carl Marks Advisors. “It is gratifying to assist a 100-year-old business complete a key acquisition of a more than 50-year-old family-owned business, fortifying the legacies of both world-class organizations.”

“We are extremely appreciative of Carl Marks Securities’ leadership and guidance throughout the transaction process,” said Thomas D. Hull III, President and Chief Executive Officer at Kewaunee. “Their team played an important role in formalizing our preexisting partnership with Nu Aire, providing us with insights we might not have considered and effective ways to align our businesses to meet the diverse needs of end-users in laboratory furnishings.”

“The acquisition of Nu Aire is a strategic move that will significantly enhance our position in the industry,” added Don Gardner, Chief Financial Officer at Kewaunee. “This achievement would not have been possible without the technical expertise and analytical rigor provided by Carl Marks Securities. Their dedication and in-depth understanding of the complexities of this deal were instrumental in guiding us through every step of the process.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”